کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
11019359 | 1718113 | 2018 | 146 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Therapeutic targeting of cathepsin C: from pathophysiology to treatment
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ANCAPapillon-Lefèvre syndromeAATDPPKPR3anti-neutrophil cytoplasmic autoantibodyMip1αα1-antitrypsinHMSGPAAATAAVMPANSPPLSCATMMPMPO - DFONETs - NET هاmicroscopic polyangiitis - polyangiitis میکروسکوپیROS - ROSElastase - الاستازneutrophil elastase - الاستاز نوتروفیلinterleukin - اینترلوکینChronic obstructive pulmonary disease - بیماری مزمن انسدادی ریهCOPD - بیماری مزمن انسدادی ریهneutrophil extracellular traps - تله های خارج سلولی نوتروفیلMatrix metalloprotease - ماتریکس متیل پروتئازایmyeloperoxidase - میلوپراکسیداز Pharmacological targeting - هدف داروسازیANCA-associated vasculitis - واسکولیت مرتبط با ANCAproteinase 3 - پروتئیناز 3Serine proteases - پرویناین serineCathepsin C - کاتئهپسین CCathepsin - کاتپسینα1-Antitrypsin deficiency - کمبود α1-آنتی تیپسینgranulomatosis with polyangiitis - گرانولوماتوز با پلیانژیتReactive oxygen species - گونههای فعال اکسیژن
موضوعات مرتبط
علوم پزشکی و سلامت
داروسازی، سم شناسی و علوم دارویی
داروشناسی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Cathepsin C (CatC) is a highly conserved tetrameric lysosomal cysteine dipeptidyl aminopeptidase. The best characterized physiological function of CatC is the activation of pro-inflammatory granule-associated serine proteases. These proteases are synthesized as inactive zymogens containing an N-terminal pro-dipeptide, which maintains the zymogen in its inactive conformation and prevents premature activation, which is potentially toxic to the cell. The activation of serine protease zymogens occurs through cleavage of the N-terminal dipeptide by CatC during cell maturation in the bone marrow. In vivo data suggest that pharmacological inhibition of pro-inflammatory serine proteases would suppress or attenuate deleterious effects mediated by these proteases in inflammatory/auto-immune disorders. The pathological deficiency in CatC is associated with Papillon-Lefèvre syndrome (PLS). The patients however do not present marked immunodeficiency despite the absence of active serine proteases in immune defense cells. Hence, the transitory pharmacological blockade of CatC activity in the precursor cells of the bone marrow may represent an attractive therapeutic strategy to regulate activity of serine proteases in inflammatory and immunologic conditions. A variety of CatC inhibitors have been developed both by pharmaceutical companies and academic investigators, some of which are currently being employed and evaluated in preclinical/clinical trials.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Pharmacology & Therapeutics - Volume 190, October 2018, Pages 202-236
Journal: Pharmacology & Therapeutics - Volume 190, October 2018, Pages 202-236
نویسندگان
Brice Korkmaz, George H. Caughey, Iain Chapple, Francis Gauthier, Josefine Hirschfeld, Dieter E. Jenne, Ralph Kettritz, Gilles Lalmanach, Anne-Sophie Lamort, Conni Lauritzen, Monika ÅÈ©gowska, Adam Lesner, Sylvain Marchand-Adam, Sarah J. McKaig,